Are there differences in the treatment strategies and outcomes between high-risk multiple myeloma patients and those with low-risk disease and without comorbities?


https://doi.org/10.4081/hmr.v2i7.407
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 147
PDF: 199
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

It is well recognized that multiple myeloma (MM) is a B-cell malignancy with great variability in clinical outcome: Median survival times are approximately 3 years with standard-dose therapy and about 4 to 5 years with intensive treatment programs, but survival may range between only a few months and more than 10 years. Therefore, it has been a relevant issue to identify prognostic indicators for the estimation of the individual patient’s outcome. Development of strategies to optimize treatment, particularly with the aim of risk-adapted therapies, has gained substantial importance due to the availability of novel agents for MM therapy.

Supporting Agencies


Drach, J. (2009). Are there differences in the treatment strategies and outcomes between high-risk multiple myeloma patients and those with low-risk disease and without comorbities?. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.407
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC